SAREPTA THERAPEUTICS, INC. Total Liabilities and Equity
SAREPTA THERAPEUTICS, INC. (SRPT) had Total Liabilities and Equity of $3.19 billion as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-08-05
- 2026-06-30: Liabilities and Equity $3.19B.
- 2026-03-31: Liabilities and Equity $3.18B.
- 2025-12-31: Liabilities and Equity $3.35B.
- 2025-09-30: Liabilities and Equity $3.49B.
| Period end | Liabilities and Equity |
|---|---|
| 2026-06-30 | $3.19B 10-Q · filed 2026-08-05 |
| 2026-03-31 | $3.18B 10-Q · filed 2026-05-06 |
| 2025-12-31 | $3.35B 10-Q · filed 2026-08-05 |
| 2025-09-30 | $3.49B 10-Q · filed 2025-11-06 |
| 2025-06-30 | $3.68B 10-Q · filed 2025-08-06 |
| 2025-03-31 | $3.47B 10-Q · filed 2025-05-06 |
| 2024-12-31 | $3.96B 10-K · filed 2026-03-02 |
| 2024-09-30 | $3.60B 10-Q · filed 2024-11-06 |
| 2024-06-30 | $3.42B 10-Q · filed 2024-08-07 |
| 2024-03-31 | $3.22B 10-Q · filed 2024-05-01 |
| 2023-12-31 | $3.26B 10-K · filed 2025-02-28 |
| 2023-09-30 | $3.11B 10-Q · filed 2023-11-01 |
| 2023-06-30 | $3.13B 10-Q · filed 2023-08-02 |
| 2023-03-31 | $3.06B 10-Q · filed 2023-05-02 |
| 2022-12-31 | $3.13B 10-K · filed 2024-02-28 |
| 2022-09-30 | $3.16B 10-Q · filed 2022-11-02 |
| 2022-06-30 | $3.00B 10-Q · filed 2022-08-02 |
| 2022-03-31 | $3.06B 10-Q · filed 2022-05-04 |
| 2021-12-31 | $3.15B 10-K · filed 2023-02-28 |
| 2021-09-30 | $2.66B 10-Q · filed 2021-11-03 |
| 2021-06-30 | $2.76B 10-Q · filed 2021-08-04 |
| 2021-03-31 | $2.77B 10-Q · filed 2021-05-05 |
| 2020-12-31 | $2.98B 10-K · filed 2022-03-01 |
| 2020-09-30 | $2.78B 10-Q · filed 2020-11-05 |
| 2020-06-30 | $2.88B 10-Q · filed 2020-08-05 |
| 2020-03-31 | $2.95B 10-Q · filed 2020-05-06 |
| 2019-12-31 | $1.82B 10-K · filed 2021-03-01 |
| 2019-09-30 | $1.70B 10-Q · filed 2019-11-07 |
| 2019-06-30 | $1.75B 10-Q · filed 2019-08-07 |
| 2019-03-31 | $1.96B 10-Q · filed 2019-05-08 |
| 2018-12-31 | $1.64B 10-K · filed 2020-02-26 |
| 2018-09-30 | $1.18B 10-Q · filed 2018-10-31 |
| 2018-06-30 | $1.25B 10-Q · filed 2018-08-08 |
| 2018-03-31 | $1.30B 10-Q · filed 2018-05-03 |
| 2017-12-31 | $1.31B 10-K · filed 2019-02-28 |
| 2017-09-30 | $800.28M 10-Q · filed 2017-11-01 |
| 2017-06-30 | $450.14M 10-Q · filed 2017-08-03 |
| 2017-03-31 | $511.53M 10-Q · filed 2017-05-04 |
| 2016-12-31 | $424.10M 10-K · filed 2018-03-01 |
| 2016-09-30 | $487.31M 10-Q · filed 2016-11-07 |
| 2016-06-30 | $204.07M 10-Q · filed 2016-08-09 |
| 2016-03-31 | $213.36M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $273.78M 10-K · filed 2017-02-28 |
| 2015-09-30 | $184.75M 10-Q · filed 2015-11-05 |
| 2015-06-30 | $231.71M 10-Q · filed 2015-08-06 |
| 2015-03-31 | $242.71M 10-Q · filed 2015-05-07 |
| 2014-12-31 | $295.03M 10-K · filed 2016-02-25 |
| 2014-09-30 | $319.06M 10-Q · filed 2014-11-06 |
| 2014-06-30 | $337.31M 10-Q · filed 2014-08-07 |
| 2014-03-31 | $275.39M 10-Q · filed 2014-05-08 |
| 2013-12-31 | $291.57M 10-K · filed 2015-02-26 |
| 2013-09-30 | $304.48M 10-Q · filed 2013-11-12 |
| 2013-06-30 | $183.63M 10-Q · filed 2013-08-08 |
| 2013-03-31 | $193.34M 10-Q · filed 2013-05-09 |
| 2012-12-31 | $204.99M 10-K · filed 2014-03-03 |
| 2012-09-30 | $53.08M 10-Q · filed 2012-11-07 |
| 2012-06-30 | $42.10M 10-Q · filed 2012-08-07 |
| 2012-03-31 | $46.65M 10-Q · filed 2012-05-10 |
| 2011-12-31 | $54.37M 10-K · filed 2013-03-15 |
| 2011-09-30 | $61.08M 10-Q · filed 2011-11-08 |
| 2011-06-30 | $74.93M 10-Q · filed 2011-08-08 |
| 2010-12-31 | $45.98M 10-K · filed 2012-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |